Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections-Reference-Cited by-同舟云学术

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Published:2017-07 Issue:7 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

King Madeline¹,Heil Emily²,Kuriakose Safia³,Bias Tiffany⁴,Huang Vanthida⁵,El-Beyrouty Claudine⁶,McCoy Dorothy⁷,Hiles Jon⁸,Richards Lynette³,Gardner Julianne⁹,Harrington Nicole⁹,Biason Kenneth³,Gallagher Jason C.¹⁰

Affiliation:

1. Philadelphia College of Pharmacy, Philadelphia, Pennsylvania, USA

2. University of Maryland School of Pharmacy, Baltimore, Maryland, USA

3. St. Joseph's Regional Medical Center, Paterson, New Jersey, USA

4. Hahnemann University Hospital, Philadelphia, Pennsylvania, USA

5. HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, USA

6. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA

7. Hackensack University Medical Center, Hackensack, New Jersey, USA

8. IU Health University Hospital, Indianapolis, Indiana, USA

9. Christiana Hospital, Newark, Delaware, USA

10. Temple University School of Pharmacy, Philadelphia, PA, USA

Abstract

ABSTRACT Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00449-17

Reference12 articles.

1. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

2. Deaths Attributable to Carbapenem-ResistantEnterobacteriaceaeInfections

3. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

4. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

5. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children;Drug Design, Development and Therapy;2024-07

2. Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use;World Journal of Emergency Surgery;2024-06-08

3. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis;Infectious Diseases and Therapy;2024-05-31

4. Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis;Infection;2024-05-13

5. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study;Frontiers in Cellular and Infection Microbiology;2024-05-08